Published 14 hours ago • loading... • Updated 8 hours ago

New Molecular Test Could Double Leukemia Survival Rates

Researchers reported on April 28, 2025, that a new bone marrow test can predict leukemia relapse earlier in patients treated in remission in the UK.
This development follows concerns that acute myeloid leukemia causes abnormal white blood cells to spread rapidly and relapse often occurs within two years after chemotherapy remission.
The study involved 637 remission patients monitored over three years using either standard care or enhanced gene testing detecting mutations in NPM1 and FLT3 genes to find minimal residual disease.
Gene mutation testing increased survival rates by 50% compared to standard monitoring by allowing doctors to restart treatment while patients remain healthy and avoid full relapse emergencies.
Researchers and clinicians hope this sensitive test becomes routine care worldwide to improve long-term survival and offer new strategies for managing this aggressive cancer.

Insights by Ground AI

Does this summary seem wrong?

40 Articles

All

Left

Center

Right

ABC FOX Montana

+38 Reposted by 38 other sources

Center

New Molecular Test Could Double Leukemia Survival Rates

Key Takeaways

8 hours ago·Missoula, United States

Read Full Article

OKDIARIO

This is the drug used for diabetes that can prevent a form of leukemia.

Acute myeloid leukemia (AML) is the most common type of leukemia in adults. It is characterized by the fact that the bone marrow produces large amounts of altered blood cells. It usually gets worse quickly unless it is treated. It is also known as acute myelogenous or myelocytic leukemia and acute non-lymphocytic leukemia.Thanks to advances in diagnosis, people who have a high risk of developing this disease can be identified years earlier by bl…

14 hours ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year